search
Back to results

Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Sitagliptin phosphate anhydrous formulation
Comparator: sitagliptin phosphate monohydrate form
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Subject is in good health
  • Female subjects must have a negative pregnancy test
  • Subject is within 30% of ideal body weight
  • Subject does not smoke
  • Subject agrees to follow the study guidelines

Exclusion Criteria:

  • Subject has a history of any illness that might confound the results of the study or make participation unsafe for the subject
  • Subject has a history of hypoglycemia
  • Subject has a history of any hepatic disease
  • Subject is taking any oral, parenteral, topical or implantable contraceptives

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    1

    2

    Arm Description

    Sitagliptin anhydrous formulation

    Sitagliptin monohydrate FMI formulation

    Outcomes

    Primary Outcome Measures

    Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
    Area Under the Plasma Concentration-Time Curve and peak concentration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
    Peak Plasma Concentration (Cmax) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
    Peak Plasma concentration (Cmax) for the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)

    Secondary Outcome Measures

    Full Information

    First Posted
    July 21, 2009
    Last Updated
    August 18, 2015
    Sponsor
    Merck Sharp & Dohme LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00944450
    Brief Title
    Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)
    Official Title
    An Open-Label, Randomized, 2-Period, Single-Dose, Balanced, Crossover Study in Healthy Subjects to Establish the Bioequivalence of Tablet Formulations Containing the Anhydrous and Monohydrate (FMI) Forms of MK0431
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    August 2004 (undefined)
    Primary Completion Date
    September 2004 (Actual)
    Study Completion Date
    November 2004 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck Sharp & Dohme LLC

    4. Oversight

    5. Study Description

    Brief Summary
    This study will establish that the MK0431 100 mg anhydrous formulation tablets are bioequivalent to the MK0431 100 mg monohydrate final market image (FMI) tablets.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes Mellitus

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Crossover Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    12 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    1
    Arm Type
    Active Comparator
    Arm Description
    Sitagliptin anhydrous formulation
    Arm Title
    2
    Arm Type
    Active Comparator
    Arm Description
    Sitagliptin monohydrate FMI formulation
    Intervention Type
    Drug
    Intervention Name(s)
    Sitagliptin phosphate anhydrous formulation
    Intervention Description
    Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.
    Intervention Type
    Drug
    Intervention Name(s)
    Comparator: sitagliptin phosphate monohydrate form
    Intervention Description
    Single dose sitagliptin 100 mg tablets [monohydrate Final Market Image (FMI) form] in one of two treatment periods.
    Primary Outcome Measure Information:
    Title
    Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
    Description
    Area Under the Plasma Concentration-Time Curve and peak concentration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
    Time Frame
    Through 72 Hours Following the Administration of the Medication
    Title
    Peak Plasma Concentration (Cmax) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
    Description
    Peak Plasma concentration (Cmax) for the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
    Time Frame
    Through 72 Hours Following the Administration of the Medication

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    55 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Subject is in good health Female subjects must have a negative pregnancy test Subject is within 30% of ideal body weight Subject does not smoke Subject agrees to follow the study guidelines Exclusion Criteria: Subject has a history of any illness that might confound the results of the study or make participation unsafe for the subject Subject has a history of hypoglycemia Subject has a history of any hepatic disease Subject is taking any oral, parenteral, topical or implantable contraceptives
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Monitor
    Organizational Affiliation
    Merck Sharp & Dohme LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)

    We'll reach out to this number within 24 hrs